Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

作     者：Pau Montesinos 

作者机构：From Hospital Universitari i Politècnic La Fe Valencia (P.M.) and Hospital Universitario Germans Trias i Pujol-Institut Català d'Oncologia Badalona Josep Carreras Research Institute Universitat Autònoma de Barcelona Badalona (S.V.) - both in Spain Institut Universitaire du Cancer de Toulouse Oncopole Centre Hospitalier Universitaire de Toulouse Toulouse (C.R.) and Institut Gustave Roussy Villejuif (S.B.) - both in France Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne Gdansk Poland (E.Z.) the Institute of Hematology and Hospital of Blood Disease Peking Union Medical College Tianjin China (J.W.) Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda Milan (G.B.) Hannover Medical School Hannover (M.H.) and Ulm University Hospital Ulm (H.D.) - both in Germany Ribeirão Preto School of Medicine University of São Paulo Ribeirão Preto Brazil (R.T.C.) Princess Margaret Cancer Centre Toronto (A.C.S.) China Medical University Taichung Taiwan (S.-P.Y.) and Servier Pharmaceuticals Boston (S.R.D. J.H. S.S.P. D.A.G.). 

出 版 物：《四川生理科学杂志》 (Sichuan Journal of Physiological Sciences)

年 卷 期：2022年第44卷第3期

页      面：415-415页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Agios Pharmaceuticals, (NCT03173248) Agios Pharmaceuticals 

主　　题：IDH1 frequent population. 

摘      要：Conclusions:Ivosidenib and azacitidine showed significant clinical benefit as compared with placebo and azacitidine in this difficult-to-treat *** neutropenia and infections were less frequent in the ivosidenib-and-azacitidine group than in the placebo-and-azacitidine group,whereas neutropenia and bleeding were more frequent in the ivosidenib-and-azacitidine group.(Funded by Agios Pharmaceuticals and Servier Pharmaceuticals;AGILE *** number,NCT03173248.).